[Correction added after online publication 27 April 2011]
Translational neuroprotection research in glaucoma: a review of definitions and principles
Article first published online: 27 APR 2011
© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 40, Issue 4, pages 350–357, May/June 2012
How to Cite
Casson, R. J., Chidlow, G., Ebneter, A., Wood, J. P., Crowston, J. and Goldberg, I. (2012), Translational neuroprotection research in glaucoma: a review of definitions and principles. Clinical & Experimental Ophthalmology, 40: 350–357. doi: 10.1111/j.1442-9071.2011.02563.x
- Issue published online: 14 JUN 2012
- Article first published online: 27 APR 2011
- Accepted manuscript online: 15 MAR 2011 05:18AM EST
- Received 19 December 2010; accepted 17 February 2011.
- glaucoma medical therapy;
- glaucoma medication
The maintenance of vision, through prevention and attenuation of neuronal injury in glaucoma, forms the basis of current clinical practice. Currently, the reduction of intraocular pressure is the only proven method to achieve these goals. Although this strategy enjoys considerable success, some patients progress to blindness; hence, additional management options are highly desirable. Several terms describing treatment modalities of neuronal diseases with potential applicability to glaucoma are used in the literature, including neuroprotection, neurorecovery, neurorescue and neuroregeneration. These phenomena have not been defined within a coherent framework. Here, we suggest a set of definitions, postulates and principles to form a foundation for the successful translation of novel glaucoma therapies from the laboratory to the clinic.